Can Amlodipine Cause Hyponatremia?

Amlodipine can cause hyponatremia, but it does so rarely. Most of the evidence linking this widely prescribed calcium channel blocker to low blood sodium comes from individual case reports and pharmacovigilance signals rather than from large clinical trials designed to measure it. A large Swedish case-control study found that the risk is concentrated in the first weeks after starting the drug and fades with continued use, which helps explain why this side effect surprises both patients and prescribers when it does appear.

What the Pharmacovigilance Data Show

Pharmacovigilance systems collect spontaneous reports of suspected adverse drug reactions from doctors, pharmacists, and patients. These reports cannot prove causation on their own, but when a drug shows up more often than expected in connection with a particular problem, it generates a “safety signal” that warrants closer attention. An analysis of 659 hyponatremia cases reported to the Spanish Pharmacovigilance System found that amlodipine carried a statistically significant reporting odds ratio of about 3.4 for hyponatremia, meaning reports of low sodium were roughly three and a half times more common with amlodipine than would be expected by chance.¹ That signal was smaller than for several other drugs in the same analysis, including some angiotensin receptor blockers, but it was real and consistent enough to register.

A review of the broader literature on drug-induced hyponatremia describes the evidence for calcium channel blockers as “restricted to case reports” and notes that amlodipine is the one most frequently implicated among the drugs in its class.² This partly reflects amlodipine’s popularity; it is one of the most widely prescribed blood pressure medications in the world, so even a very low-frequency side effect will generate more reports than a similar rate would for a less-used drug. Still, the pattern across multiple pharmacovigilance databases and clinical reviews consistently points to amlodipine rather than other calcium channel blockers, which suggests something about the drug itself may matter.

How Amlodipine Could Lower Sodium

The mechanism is not as straightforward as it is with, say, thiazide diuretics, where the drug directly interferes with sodium reabsorption in the kidneys. With amlodipine, researchers have proposed a few overlapping pathways that could contribute.

The most studied is increased urinary sodium excretion. A randomized trial in patients with mild-to-moderate hypertension found that amlodipine significantly increased the amount of sodium excreted in the urine, while leaving kidney filtration rate, plasma renin activity, and aldosterone levels essentially unchanged.³ That combination is interesting: the kidney was flushing out more sodium, but the hormonal systems that normally respond to sodium loss did not kick in to compensate. In most people, the body adjusts and sodium levels stay within the normal range. But in someone whose compensatory mechanisms are already compromised, that extra sodium loss could tip the balance.

Animal research adds another layer. In spontaneously hypertensive rats, amlodipine at higher doses increased both urine flow and sodium excretion, and the effect appeared to work by blocking calcium-dependent sodium reabsorption at the kidney tubule.⁴ This effect was specific to the hypertensive animals; normotensive rats did not show the same response, which suggests that hypertension itself may alter the kidney in ways that make it more sensitive to calcium channel blockade. If that principle holds in humans, it could help explain why hyponatremia surfaces only in certain patients.

There is also a fluid-distribution angle. A study comparing amlodipine to an ACE inhibitor in hypertensive patients found that roughly seven in ten patients in the amlodipine group showed an increase in total body water, mainly from extracellular fluid accumulation.⁵ This kind of fluid shift, if it dilutes blood sodium faster than the body can compensate, could contribute to dilutional hyponatremia. This same mechanism is responsible for the ankle swelling that some amlodipine users notice, which is amlodipine’s best-known side effect and something prescribers watch for routinely.

The Risk Is Highest Right After Starting the Drug

Perhaps the most practically useful finding comes from a large Swedish case-control study that examined severe hyponatremia across four major classes of blood pressure medications. When the researchers looked at calcium channel blockers as a whole, the overall adjusted odds ratio was actually below one (0.86), meaning ongoing users appeared to have a slightly lower-than-average risk of severe hyponatremia.⁶ At first glance, that looks reassuring. But when they separated newly initiated therapy from ongoing use, the picture changed dramatically.

For patients who had recently started a vascular calcium channel blocker (the class amlodipine belongs to), the adjusted odds ratio for severe hyponatremia nearly doubled, to about 1.95. For ongoing therapy, it dropped to 0.82. The same pattern held across all four drug classes studied: the elevated risk was almost entirely concentrated in the first weeks of treatment and then diminished.⁶ This early-treatment window matters because it tells you when to be alert. If you have been taking amlodipine for months or years without problems, the data suggest the risk of drug-induced hyponatremia is very low. It is the transition period, when the body is still adjusting to the drug, that deserves more attention.

Thiazide diuretics offer a useful comparison. A review of pharmacological mechanisms behind drug-induced hyponatremia noted that the risk of thiazide-induced hyponatremia was nearly fifty-fold higher in the first week of treatment, then gradually declined, though patients on ongoing therapy still faced more than triple the baseline risk.⁷ So while both drug classes show the early-treatment spike, thiazides carry a far larger and more persistent risk. That difference is part of why thiazide-induced hyponatremia is a textbook topic while amlodipine-induced hyponatremia still surprises many clinicians.

How Amlodipine Compares to Other Blood Pressure Drugs

The same Swedish study ranked all four major antihypertensive classes by their overall association with severe hyponatremia. ACE inhibitors had the highest odds ratio among newly initiated drugs (about 2.2), followed by angiotensin receptor blockers, then beta blockers, then calcium channel blockers at the bottom (about 1.6).⁶ Among ongoing users, none of the four classes showed a meaningfully elevated risk. The takeaway here is that CCBs are not uniquely dangerous in this regard. Every commonly prescribed blood pressure medication carries some early-treatment hyponatremia risk, and CCBs actually sit at the lower end of the spectrum.

The Spanish pharmacovigilance data tell a somewhat different story by drug class, showing angiotensin receptor blockers like irbesartan and valsartan with much higher reporting odds ratios than amlodipine.¹ These two datasets are not directly comparable since they use different methods and populations, but the consistent message is that amlodipine’s risk is real but modest relative to other drugs in the same therapeutic space, and far below the risk seen with thiazide diuretics.

Among calcium channel blockers specifically, a review of drug-induced hyponatremia observed that the condition is rare for both subclasses (dihydropyridines like amlodipine and non-dihydropyridines like verapamil and diltiazem), but dihydropyridines, and amlodipine in particular, account for a slightly larger share of reports.⁷ Whether that reflects a true pharmacological difference or simply the fact that amlodipine is prescribed vastly more often remains an open question.

Who Faces Higher Risk

The typical profile for amlodipine-associated hyponatremia is an older adult who has recently started the drug. Clinical reviews consistently flag advanced age as the common thread linking most reported cases.⁷ This is not unique to amlodipine; aging blunts the kidney’s ability to regulate water and sodium, lowers baseline sodium reserves, and often introduces other drugs that independently affect sodium. The elderly are overrepresented in hyponatremia cases across virtually every drug class.

Beyond age, the fluid-retention effect of amlodipine may matter more in certain patients. The study that found increased total body water in most amlodipine users also reported that six of the thirty-two patients who developed this fluid increase were women who went on to develop ankle edema.⁵ Peripheral edema from amlodipine is already well documented, but the link to extracellular water expansion suggests that patients who are prone to fluid retention, including those with heart failure, liver disease, or kidney impairment, could be more vulnerable to dilutional hyponatremia as well.

People taking multiple medications that independently lower sodium face compounding risk. If you are already on a thiazide diuretic, an SSRI antidepressant, or an anticonvulsant and your doctor adds amlodipine, the cumulative effect on sodium homeostasis is harder to predict than the effect of any single drug. Polypharmacy is one of the biggest practical risk factors for drug-induced hyponatremia in older adults, and it often matters more than any individual drug’s contribution.

Recognizing and Managing It

Hyponatremia can be subtle. Mild drops in sodium often cause symptoms that are easy to attribute to other things: fatigue, mild confusion, unsteadiness, nausea, or headache. In elderly patients, these can be mistaken for normal aging or early cognitive decline. This is one reason drug-induced hyponatremia goes underdiagnosed; the patient does not connect the new medication with the new symptom, and the clinician may not check a sodium level unless the symptoms are severe.

The diagnostic process involves checking serum sodium and then working backward through the potential causes. If amlodipine is suspected, the standard approach is to discontinue the drug and see whether sodium levels recover. In one published case, stopping amlodipine and switching to the beta blocker nebivolol led to sodium rising to 131 mmol/L.⁸ That value is still technically below the normal range (135-145 mmol/L), but the upward trend after drug withdrawal is the key indicator that the original medication was contributing to the problem. Full recovery of sodium levels can take days to weeks depending on how low the level fell and whether other contributing factors are also being addressed.

If you are concerned about low sodium while taking amlodipine, the practical steps are straightforward. Talk to your prescriber about checking a basic metabolic panel, which includes serum sodium. If the level is low, a trial off the drug is both diagnostic and therapeutic. Amlodipine is never the only option for blood pressure control; alternatives in other drug classes can often achieve comparable results without the same effect on sodium.

Amlodipine’s Fluid Effects Beyond Sodium

Ankle swelling is the side effect most amlodipine users have heard about, and it connects to the sodium story in an interesting way. Amlodipine dilates arterioles more than it dilates the veins that drain the capillary beds. This pressure mismatch forces fluid out of capillaries and into surrounding tissues, producing edema that is most noticeable in the lower legs. About seven in ten patients in one study showed measurable increases in total body water during amlodipine treatment, driven mainly by interstitial fluid accumulation rather than by an increase in blood volume itself.⁵

This is different from the fluid retention caused by, say, heart failure, where the body is holding on to salt and water because the heart is not pumping effectively. With amlodipine, the kidneys are actually excreting more sodium than usual, as the renal hemodynamics studies show.³ So the body may be losing sodium through the kidneys while simultaneously accumulating water in the tissues, a combination that, in vulnerable patients, could push blood sodium levels downward. Most people’s regulatory systems handle this without trouble, but for an older patient with limited physiological reserve, the dual hit of increased sodium loss and increased water retention may be enough to cause clinically meaningful hyponatremia.

Why This Side Effect Stays Under the Radar

There are a few reasons amlodipine-induced hyponatremia is not better known, even among clinicians. The first is simply frequency. Thiazide diuretics cause hyponatremia often enough that every medical student learns about it. SSRIs and anticonvulsants are also well-established culprits. Amlodipine, by contrast, produces clinically significant hyponatremia so infrequently that a prescribing physician could go an entire career without seeing a clear-cut case. The clinical literature is dominated by isolated case reports rather than cohort-level data.²

The second reason is the early-treatment window effect. Because the risk falls off with continued use, patients who develop hyponatremia in the first weeks may have their medication adjusted before anyone attributes the sodium drop to amlodipine specifically. Many of these patients are elderly, newly diagnosed with hypertension, and starting multiple medications at once, making it hard to pin the problem on any single drug. The Swedish population study was valuable precisely because it was large enough to tease apart the new-versus-ongoing distinction that individual case reports cannot easily resolve.⁶

The third reason is that drug labels and prescribing references do not always list hyponatremia prominently for amlodipine. Prescribers checking for known side effects see edema, flushing, dizziness, and fatigue. Hyponatremia may appear in post-marketing reports or pharmacovigilance databases but not in a prominent warning, which means it does not enter the mental checklist many clinicians run through when evaluating a new symptom in a patient on amlodipine. For patients who want to be proactive, simply being aware that the association exists is itself useful. Knowing to ask about a sodium check during the first month or two of treatment, especially if you are older or taking other medications that affect sodium, is a reasonable precaution that costs nothing and could catch a problem early.